PHARMACOKINETICS OF SIMEPREVIR (TMC435) IN VOLUNTEERS WITH MODERATE OR SEVERE HEPATIC IMPAIRMENT

被引：13
|
作者：
Ouwerkerk-Mahadevan, S. [1 ]
Simion, A. [2 ]
Spittaels, K. [2 ]
Beumont-Mauviel, M. [2 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Infect Dis BVBA, Beerse, Belgium
来源：
JOURNAL OF HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
10.1016/S0168-8278(13)60889-2
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
887
引用
下载
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [41] EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON QUIZARTINIB PHARMACOKINETICS
    Zahir, H.
    Lasseter, K.
    Marbury, T.
    Rondon, J.
    Bermudez, Y.
    Gammon, G.
    Kamel, Y. Mostafa
    Said, N.
    Hsu, C.
    Abutarif, M.
    Zheng, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S20 - S20
  • [42] Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
    David Schnell
    Susanne Buschke
    Holger Fuchs
    Dietmar Gansser
    Rainer-Georg Goeldner
    Martina Uttenreuther-Fischer
    Peter Stopfer
    Sven Wind
    Marc Petersen-Sylla
    Atef Halabi
    Rüdiger Koenen
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 267 - 275
  • [43] Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment
    Luis Almeida
    J. Hendrick Potgieter
    Joana Maia
    M. Alida Potgieter
    Fernando Mota
    P. Soares-da-Silva
    European Journal of Clinical Pharmacology, 2008, 64 : 267 - 273
  • [44] Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment
    Mehmet Akce
    Anthony El-Khoueiry
    Sarina A. Piha-Paul
    Emeline Bacque
    Peng Pan
    Zhi-Yi Zhang
    Reginald Ewesuedo
    Divya Gupta
    Yongqiang Tang
    Ashley Milton
    Stefan Zajic
    Patricia L. Judson
    Cindy L. O’Bryant
    Cancer Chemotherapy and Pharmacology, 2021, 88 : 825 - 836
  • [45] EFFECT OF MODERATE HEPATIC IMPAIRMENT ON THE SAFETY AND PHARMACOKINETICS OF REZAFUNGIN
    Ong, Voon
    Sandison, Taylor
    Melara, Rebeca
    Marbury, Thomas
    Huguet, Jade
    Jandourek, Alena
    Flanagan, Shawn
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 334 - 334
  • [46] Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Ozanimod
    Zhang, Peijin
    Hosein, Fareeda
    Yu, Kyungha
    Walker, Susan
    Syto, Mary
    Tirucherai, Giridhar
    Murthy, Bindu
    Tatosian, Daniel
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 976 - 976
  • [47] Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics
    Khalilieh, Sauzanne
    Yee, Ka Lai
    Liu, Rachael
    Fan, Li
    Sanchez, Rosa I.
    Auger, Patrice
    Triantafyllou, Ilias
    Stypinski, Daria
    Lasseter, Kenneth C.
    Marbury, Thomas
    Iwamoto, Marian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (06): : 777 - 783
  • [48] Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
    Gupta, Neeraj
    Hanley, Michael J.
    Venkatakrishnan, Karthik
    Perez, Raymond
    Norris, Robin E.
    Nemunaitis, John
    Yang, Huyuan
    Qian, Mark G.
    Falchook, Gerald
    Labotka, Richard
    Fu, Siqing
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) : 728 - 738
  • [49] Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
    Kumada, Hiromitsu
    Hayashi, Norio
    Izumi, Namiki
    Okanoue, Takeshi
    Tsubouchi, Hirohito
    Yatsuhashi, Hiroshi
    Kato, Mai
    Rito, Ki
    Komada, Yuji
    Seto, Chiharu
    Goto, Shoichiro
    HEPATOLOGY RESEARCH, 2015, 45 (05) : 501 - 513
  • [50] Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study
    Norio Hayashi
    Chiharu Seto
    Mai Kato
    Yuji Komada
    Shoichiro Goto
    Journal of Gastroenterology, 2014, 49 : 138 - 147
12345